AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Promising Results Observed In Topical Alprostadil Cream Trial.(Brief Article)
2001 NOV 15 - (NewsRx.com & NewsRx.net) -- NexMed, Inc. announced that Phase I clinical trial data from the use of Femprox (active ingredient alprostadil) in women with female sexual arousal disorder (FSAD) were encouraging.
The study was conducted at the UMDNJ Robert Wood Johnson Medical School. Femprox is NexMed's proprietary cream for the treatment of FSAD and incorporates alprostadil with the patented NexACT transdermal penetration enhancement technology. In May 2001, NexMed completed its Phase I clinical program for Femprox, and initiated a Phase II study, which is enrolling up to 110 patients at up to 12 research sites throughout the U.S.
The study "Topical alprostadil in the treatment of female sexual arousal disorder," was published in the October-December 2001 issue of the Journal of Sex and Marital Therapy. The trial evaluated the efficacy and safety of three doses of Femprox cream in patients with FSAD. In this Phase I study, each patient was administered a single dose of placebo followed by escalating doses of the active drug at two-week intervals.
The publication, ...
- NexMed to Initiate 400 Femprox(R) Clinical Study in China For Female Sexual...
- Press release article from: PR Newswire March 2, 2004 700+ words
...transdermal enhancer. In NexMed's U.S. Phase...women diagnosed with FSAD completed the four...Board protocol, NexMed subsequently explored...aged 21-45 with FSAD. The clinical efficacy...advancement of its FSAD product, Femprox...serious condition." NexMed also announced that...
- NexMed to initiate 400 Femprox clinical study in China for female sexual...
- News wire article from: Asia Africa Intelligence Wire March 2, 2004 700+ words
...study is based on results from NexMed's clinical studies to date...female sexual arousal disorder (FSAD). Femprox, recently profiled...NexACT transdermal enhancer. In NexMed's US Phase II study for Femprox...menopausal women diagnosed with FSAD completed the four-week clinical...
- NexMed Announces Positive Femprox Study Results at AUA Annual Meeting in San...
- Press release article from: PR Newswire May 23, 2005 700+ words
...is no pharmaceutical product approved for treating FSAD. NexMed is among the front-runners in the race to develop a safe and effective treatment for FSAD. About NexMed, Inc. NexMed, Inc. is an emerging drug developer...
- NexMed Completes Femprox Phase 2 Study; - First Topical Treatment Tested in At...
- Press release article from: PR Newswire April 2, 2002 700+ words
...women diagnosed with FSAD. Femprox(R...vasodilator, with NexMed's NexACT(R...The causes of FSAD are complex and...fatigue. About NexMed, Inc. NexMed...dysfunction and FSAD, respectively. NexMed is also developing...
- NexMed Announces 5th Patent Allowance for Femprox(R); - Company to Report First...
- Press release article from: PR Newswire April 21, 2004 700+ words
...sexual arousal disorder ("FSAD"), and provides U...Joseph Mo, C.E.O. of NexMed, commented, "We are...transdermal enhancer. NexMed recently announced its...patients diagnosed with FSAD. NexMed also announced that on...
- NexMed Closes Enrollment For Femprox at Home Use Study.
- Press release article from: PR Newswire January 30, 2002 700+ words
...Patients who suffer from FSAD have symptoms that include...arousal. The causes of FSAD are complex and are suggested...stress and fatigue. About NexMed, Inc. NexMed, Inc...erectile dysfunction and FSAD, respectively. NexMed is also developing Viratrol...
- NexMed to Present At the Int'l Society for the Study of Women's Sexual Health.
- Press release article from: PR Newswire October 10, 2002 700+ words
...Southern California and a NexMed consultant, will present...arousal disorder ("FSAD"), at the Annual...topical treatment for FSAD." About NexMed, Inc. NexMed, Inc...erectile dysfunction and FSAD, respectively. NexMed is also developing...
- NexMed's Female Sexual Arousal Disorder Product Enters Phase 2 Clinical Trial.
- Press release article from: PR Newswire May 21, 2001 700+ words
...milestone achieved by NexMed. We remain among...commercial treatment for FSAD." Dr. Mo further...projected size of the FSAD market may be as...of ED." About NexMed, Inc. NexMed...treating ED and FSAD, respectively. NexMed is also developing...
- NexMed Announces NDA Filing in Singapore.
- Press release article from: PR Newswire November 27, 2001 700+ words
...take oral ED medication. NexMed is also conducting a Phase...sexual arousal disorder ("FSAD"), which will enroll...patients at 12 sites. About NexMed, Inc. NexMed, Inc...cream for treating ED and FSAD, respectively. NexMed is also developing Viratrol...
- NexMed Announces $5 Million Line of Credit.
- Press release article from: PR Newswire February 21, 2001 700+ words
...ED") and Femprox(TM), NexMed's topical treatment for female sexual arousal disorder ("FSAD"). NexMed projects that the East Windsor...Femprox topical treatment for FSAD(R). In addition, NexMed is developing Viratrol(R...
Source: HighBeam Research, Promising Results Observed In Topical Alprostadil Cream Trial.(Brief...